Compare ICG & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICG | PYXS |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 71.6M |
| IPO Year | 2022 | 2021 |
| Metric | ICG | PYXS |
|---|---|---|
| Price | $1.09 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.25 | ★ $6.75 |
| AVG Volume (30 Days) | 28.8K | ★ 274.0K |
| Earning Date | 02-26-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $0.84 |
| 52 Week High | $4.13 | $5.55 |
| Indicator | ICG | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 29.59 | 41.12 |
| Support Level | $0.93 | $1.29 |
| Resistance Level | $1.96 | $1.69 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 13.30 | 13.51 |
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.